Contineum Therapeutics, Inc. business relationships
Companies named in Contineum Therapeutics, Inc.’s 10-K filed 2026-03-05, and public companies whose annual reports name Contineum Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.2 / 10
- AI naming
- <1 / 100 Top 10% in its category
- Agent readiness
- 40 / 100
- AI adoption
- 0 / 100
Named in Contineum Therapeutics, Inc.’s annual report 1
“...2025, the Company has financed its operations primarily from the sale of equity securities and convertible equity securities, and a global license and development agreement (the "J&J License Agreement") the Company entered in February 2023 with Janssen Pharmaceutica NV, a Johnson & Johnson company.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.